Study of HRS-5041 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
The purpose of this study is to assess the safety, tolerability and preliminary efficacy of HRS-5041 in men with progressive metastatic castration resistant prostate cancer. The objective of this study was to determine the dose-limiting toxicity, maximum tolerance and recommended dose of HRS-5041 in phase II study.
Advanced Prostate Cancer
DRUG: HRS-5041
Dose-limiting toxicity (DLT), Up to 28 days|Maximum tolerated dose (MTD), Up to 28 days|Recommended Phase 2 Dose (RP2D) of HRS-5041, Up to 28 days
Number of participants with adverse events (AEs) evaluated using the NCI CTCAE v5.0 criteria, From the time of consent at screening until 30 days after the subject discontinues study treatment, up to 2 years|Pharmacokinetics - Area under the plasma concentration time curve (AUC), 12 weeks|Pharmacokinetics - Maximum plasma concentration (Cmax), 12 weeks|Pharmacokinetics - Time to Cmax (Tmax), 12 weeks|Prostate Specific Antigen (PSA) decline of â‰¥ 50% from baseline (PSA50), 24 months|PSA Progression Free Survival (PFS), 24 months|Objective soft tissue response defined by complete response (CR) or partial response (PR) per Prostate Cancer Clinical Trials Working Group 3 (PCWG3), 24 months|Radiographic progression free survival (rPFS), 24 months|Overall survival (OS), 24 months
The purpose of this study is to assess the safety, tolerability and preliminary efficacy of HRS-5041 in men with progressive metastatic castration resistant prostate cancer. The objective of this study was to determine the dose-limiting toxicity, maximum tolerance and recommended dose of HRS-5041 in phase II study.